Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23764687 | 0.87 | CHRM5 (0.52) | CHRM5 | |
| SCHEMBL18955115 | 0.85 | CHRM5 (0.51) | CHRM5 | |
| SCHEMBL9104477 | 0.81 | CHRM5 (0.50) | CHRM5 | |
| SCHEMBL18954837 | 0.81 | CHRM5 (0.50) | CHRM5 | |
| SCHEMBL9266561 | 0.81 | CHRM5 (0.60) | CHRM5 | |
| SCHEMBL23764714 | 0.80 | CHRM5 (0.46) | CHRM5 | |
| SCHEMBL23764648 | 0.80 | CHRM5 (0.46) | CHRM5 | |
| SCHEMBL23764711 | 0.79 | CHRM5 (0.47) | CHRM5 | |
| SCHEMBL9107184 | 0.79 | CHRM5 (0.49) | CHRM5 | |
| SCHEMBL27048738 | 0.78 | HSP90AA1 (0.46) | CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017099695-A1 | N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | ISTANBUL UNIVERSITESI REKTORLUGU (TR) | 2017-06-15 | — | — | WO | disclosed |
| EP-2032584-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Wyeth (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007146138-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | ADAMTS5, ADAMTS1, TIMP3 | CHRM5 2871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.